Article
AKT Inhibition in Solid Tumors With AKT1 Mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jul 2017
Hyman David M, Smyth Lillian M, Donoghue Mark T A, Westin Shannon N, Bedard Philippe L, Dean Emma J, Bando Hideaki, El-Khoueiry Anthony B, Pérez-Fidalgo José A, Mita Alain, Schellens Jan H M, Chang Matthew T, Reichel Jonathan B, Bouvier Nancy, Selcuklu S Duygu, Soumerai Tara E, Torrisi Jean, Erinjeri Joseph P, Ambrose Helen, Barrett J Carl, Dougherty Brian, Foxley Andrew, Lindemann Justin P O, McEwen Robert, Pass Martin, Schiavon Gaia, Berger Michael F, Chandarlapaty Sarat, Solit David B, Banerji Udai, Baselga José, Taylor Barry S
Abstract excerpt
Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary activity of AKT inhibition in AKT-mutant cancers. Patients and Methods Fifty-eight patients with advanced solid tumors were treated. The primary end point was safety; secondary end points were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.